Histamine dihydrochloride
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Clinical data | |
---|---|
Trade names | Ceplene |
License data | |
topical | |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
|
Histamine dihydrochloride (
It is also an FDA-approved[1] active ingredient for topical analgesic use for the temporary relief of minor aches and pains of muscles and joints associated with arthritis, simple backache, bruises, sprains, and strains and is available in over-the-counter (OTC) products such as Australian Dream and Golden Creme.[2] [3]
Use in leukemia
Histamine dihydrochloride is administered in conjunction with low doses of the immune-activating
The combination of histamine dihydrochloride and interleukin-2 was approved for use in AML patients within the European Union in October 2008[6] and will be marketed in the EU by the Swedish pharmaceutical company Meda. The drug is also available through a named patient program in several other countries (excluding the US).
Proposed mechanism of action
Histamine dihydrochloride acts by improving the immune-enhancing properties of IL-2, and laboratory studies have shown that this combination can induce immune-mediated killing of
References
- ^ Federal Register, volume 48, no. 27, 8 February 1983
- ^ "Australian Dream – Pain Relief". Australian Dream – Pain Relief. Retrieved 12 April 2022.
- ^ "Home". Golden Creme by Relief, Inc. 26 August 2018. Retrieved 12 April 2022.
- PMID 16556892.
- S2CID 23521141.
- ^ Committee For Medicinal Products For Human Use: Summary Of Positive Opinion for Ceplene[permanent dead link] (2008-11-25)
- PMID 7963557.